$4.72
1.29%
Nasdaq, Fri, Sep 25 2026.
ISIN
US45175G1085
Symbol
IKNA

Ikena Oncology Inc Stock price

$4.72
-0.83 14.96% 1M
-0.84 15.11% 6M
-2.18 31.59% YTD
-3.06 39.33% 1Y
-51.92 91.67% 3Y
-149.12 96.93% 5Y
-11.28 70.50% 10Y
-11.28 70.50% 20Y
Nasdaq, Closing price Fri, Sep 25 2026
+0.06 1.29%
ISIN
US45175G1085
Symbol
IKNA
Industry

Is Ikena Oncology Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,127 stocks worldwide.

Key metrics

Basic
Market capitalization
-
Enterprise Value
-
Net debt
positive
Cash
$114.1m
Shares outstanding
48.3m
Valuation (TTM | estimate)
P/E
-
P/S
- | -
EV/Sales
- | -
EV/FCF
-
P/B
-
Financial Health
Equity Ratio
89.0%
Return on Equity
-39.1%
ROCE
-
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
- | $0.0
EBITDA
-
EBIT
-
Net Income
-
Free Cash Flow
$-38.3m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-
EBIT
-
Net Income
-
Free Cash Flow
51.3%
Margin
Gross
-
EBITDA
-
EBIT
-
Net
-
Free Cash Flow
-
More
EPS
-
FCF per Share
$-0.8
Short interest
0.0%
Employees
9
Rev per Employee
$0.0

Ikena Oncology Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Ikena Oncology Inc forecast:

6x Buy
75%
2x Hold
25%

Analyst Opinions

8 Analysts have issued a Ikena Oncology Inc forecast:

Buy
75%
Hold
25%

Financial data from Ikena Oncology Inc

Dec '24
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 24 24
5% 5%
-
- Research and Development Expense 31 31
48% 48%
-
-54 -54
27% 27%
-
- Depreciation and Amortization 0.49 0.49
52% 52%
-
EBIT (Operating Income) EBIT -55 -55
28% 28%
-
Net Profit -49 -49
28% 28%
-

In millions USD.

Don't miss a Thing! We will send you all news about Ikena Oncology Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Ikena Oncology, Inc. is a clinical stage biotechnology company. It discovers and develops patient directed, biomarker driven therapies for cancer patients. Its product pipeline includes IK-930, RAS Signaling, IK-175, IK-412 and IK-007. The company was founded by Mark Manfredi and George Georgiou in February 2016 and is headquartered in Boston, MA.

Head office United States
CEO Dr. Manfredi
Employees 9
Founded 2016
Website www.ikenaoncology.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today